Nanobiotix Reports Positive Phase I/II Preliminary Data On Feasibility And Safety Of NBTXR3 In Liver Cancers Trial

Paris, France and Cambridge, Massachusetts, USA, December 14, 2016 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces a positive readout of initial data on the safety and feasibility from the first patients treated in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and metastatic tumors.

For full access, please click here.